Entity

Time filter

Source Type


Galli F.,University of Rome La Sapienza | Galli F.,University of Groningen | Manni I.,Regina Elena Cancer Institute | Piaggio G.,Regina Elena Cancer Institute | And 7 more authors.
Thyroid | Year: 2014

Background: Differentiated thyroid carcinomas originating from thyroid follicular cells are frequent tumors of the thyroid with relatively good prognosis due to improved surgical techniques and follow-up procedures. Poorly differentiated thyroid cancers, which lose iodine uptake ability, in most cases still express thyrotropin (TSH) receptors (TSHR). Therefore, the aim of this study was to radiolabel a superagonist recombinant human TSH (rhTSH) analogue for imaging poorly differentiated thyroid cancer. Methods: The TSHR superagonist, TR1401, was labeled with 99mTc using an indirect method via succinimidyl-6-hydrazinonicotinate hydrochloride conjugation. In vitro quality controls included SDS-PAGE, cysteine challenge, and cell-binding assay on TSHR positive cell lines (JP09 and ML-1). In vivo studies included tumor targeting experiments in athymic nude CD-1 mice xenografted with several different TSHR positive cells (JP09, K1, and ML-1) and TSHR negative cells (JP02) as control. Results: The superagonist rhTSH analogue TR1401 was labeled with high labeling efficiency (>95%) and high specific activity (9250MBq/mg). The labeled molecule retained its biologic activity and structural integrity. In tumor targeting experiments, a focal uptake of radiolabeled TR1401 was observed in TSHR positive cells but not in TSHR negative cells. The same observation was made in a dog with spontaneous intraglandular thyroid cancer. Conclusions: We were able to radiolabel the rhTSH superagonist analogue TR1401 with 99mTc efficiently with retention of in vitro and in vivo binding capacity to TSHR. The relative role of such novel radiopharmaceutical versus 131I scanning of thyroid cancer will require future histopathologic and clinical studies, but it may open new perspectives for presurgical staging of thyroid cancer, and diagnosis of radioiodine negative local relapses and/or distant metastases. © Copyright 2014, Mary Ann Liebert, Inc. 2014. Source


Roosli M.,Swiss Tropical and Public Health Institute | Roosli M.,University of Basel | Frei P.,Swiss Tropical and Public Health Institute | Frei P.,University of Basel | And 19 more authors.
Environmental Health: A Global Access Science Source | Year: 2010

Background. The development of new wireless communication technologies that emit radio frequency electromagnetic fields (RF-EMF) is ongoing, but little is known about the RF-EMF exposure distribution in the general population. Previous attempts to measure personal exposure to RF-EMF have used different measurement protocols and analysis methods making comparisons between exposure situations across different study populations very difficult. As a result, observed differences in exposure levels between study populations may not reflect real exposure differences but may be in part, or wholly due to methodological differences. Methods. The aim of this paper is to develop a study protocol for future personal RF-EMF exposure studies based on experience drawn from previous research. Using the current knowledge base, we propose procedures for the measurement of personal exposure to RF-EMF, data collection, data management and analysis, and methods for the selection and instruction of study participants. Results. We have identified two basic types of personal RF-EMF measurement studies: population surveys and microenvironmental measurements. In the case of a population survey, the unit of observation is the individual and a randomly selected representative sample of the population is needed to obtain reliable results. For microenvironmental measurements, study participants are selected in order to represent typical behaviours in different microenvironments. These two study types require different methods and procedures. Conclusion. Applying our proposed common core procedures in future personal measurement studies will allow direct comparisons of personal RF-EMF exposures in different populations and study areas. © 2010 Röösli et al; licensee BioMed Central Ltd. Source


Chakraborty S.,Bhabha Atomic Research Center | Balogh L.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene | Das T.,Bhabha Atomic Research Center | Polyak A.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene | And 9 more authors.
Current Radiopharmaceuticals | Year: 2016

177Lu-EDTMP is currently being investigated as a potential agent for providing palliative care to the patients suffering from bone pain due to metastatic skeletal carcinoma. The present article describes the evaluation of177Lu-EDTMP complex in four different canine patients with different types of primary and metastatic skeletal lesions with respect to its pharmacokinetic properties, dosimetry and therapeutic efficacy. The dogs were treated with a dose of ~44.4 MBq (1.2 mCi) per kg body weight of177Lu-EDTMP, synthesized in-house with high radiochemical purity (98.8 ± 0.4 %) and excellent in vitro stability. The radiopharmaceutical showed favourable pharmacokinetic properties, such as, preferential accumulation at skeletal lesion sites and fast clearance from blood and other nontarget organs through urinary route. The administered dose of the radiopharmacutical showed excellent therapeutic efficacy in case of a dog suffering from skeletal metastasis originating from primary tumor elsewhere. On the other hand, two of the remaining three patients with primary bone cancer showed stable disease intially with palliative effect. The fourth patient having metal implant induced osteosarcoma with severe limb oedema did not show any response to the treatment. © 2016 Bentham Science Publishers. Source


Necz P.P.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene | Bakos J.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene
International Journal of Occupational Medicine and Environmental Health | Year: 2014

Objectives: Nowadays more and more newly introduced light sources (tungsten-halogen, compact fluorescent (CFL) and light-emitting diode (LED) lamps) are used in households. It is important to know whether their radiation poses any possible risk for human health or not. These light sources emit optical radiation not solely in the visible spectrum. Other bands emitted by these sources, i.e., ultraviolet and infrared, are potentially hazardous for human health. The visible light, especially the blue light, could also damage human retina. The purpose of this study was to determine the ultraviolet (UV) and blue light (BL) emissions from halogen bulbs, CFLs and LED lamps, and to evaluate them from the point of view of possible health risks for general public.Material and Methods: The exposure of UV and BL emissions from 19 types of CFLs, 11 types of halogen lamps and 4 types of LED lamps produced by different manufacturers were measured at 200 mm distance from the source.Results: The exposures to UV and BL were below the International Commission on Non-Ionizing Radiation Protection (ICNIRP) exposure limits in spite of the very conservative assumption of the assessment.Conclusions: Results of this study indicate that the UV and BL radiation from the newly introduced lamps does not exceed the current exposure limit values and thus, in comparison with the former incandescent bulbs, does not result in a higher risk for general public. © 2014, Versita Warsaw and Springer-Verlag Wien. Source


Gresits I.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene | Necz P.P.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene | Janossy G.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene | Thuroczy G.,National Frederic Joliot Curie Research Institute for Radiobiology and Radiohygiene
Electromagnetic Biology and Medicine | Year: 2015

Measurements of extremely low frequency (ELF) magnetic fields were conducted in the environment of commercial laboratory equipment in order to evaluate the possible co-exposure during the experimental processes on cell cultures. Three types of device were evaluated: a cell culture CO2 incubator, a thermostatic water bath and a laboratory shaker table. These devices usually have electric motors, heating wires and electronic control systems, therefore may expose the cell cultures to undesirable ELF stray magnetic fields. Spatial distributions of magnetic field time domain signal waveform and frequency spectral analysis (FFT) were processed. Long- and short-term variation of stray magnetic field was also evaluated under normal use of investigated laboratory devices. The results show that the equipment under test may add a considerable ELF magnetic field to the ambient environmental magnetic field or to the intentional exposure to ELF, RF or other physical/chemical agents. The maximum stray magnetic fields were higher than 3 T, 20 T and 75 T in the CO2 incubator, in water bath and on the laboratory shaker table, respectively, with high variation of spatial distribution and time domain. Our investigation emphasizes possible confounding factors conducting cell culture studies related to low-level ELF-EMF exposure due to the existing stray magnetic fields in the ambient environment of laboratory equipment. © 2015 Taylor & Francis. Source

Discover hidden collaborations